id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2023-E-3236-0006,FDA,FDA-2023-E-3236,Determination of Regulatory Review Period for Purposes of Patent Extension; LEQEMBI,Notice,Determinations,2025-12-29T05:00:00Z,2025,12,2025-12-29T05:00:00Z,2026-02-28T04:59:59Z,2025-12-29T20:09:09Z,2025-23865,0,0,09000064b910a288
FDA-2023-E-3236-0005,FDA,FDA-2023-E-3236,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-08-19T04:00:00Z,2025,8,2025-08-19T04:00:00Z,,2025-08-19T21:38:35Z,,0,0,09000064b8f08595
FDA-2023-E-3236-0004,FDA,FDA-2023-E-3236,Letter from U. S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-07-24T04:00:00Z,2025,7,2025-07-24T04:00:00Z,,2025-07-25T01:10:32Z,,0,0,09000064b8e9d1de
FDA-2023-E-3236-0003,FDA,FDA-2023-E-3236,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2024-02-05T05:00:00Z,2024,2,2024-02-05T05:00:00Z,,2024-03-08T17:23:53Z,,0,0,09000064863e509d
FDA-2023-E-3236-0001,FDA,FDA-2023-E-3236,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2023-08-18T04:00:00Z,2023,8,2023-08-18T04:00:00Z,,2023-08-18T13:17:30Z,,0,0,0900006485da4b40
FDA-2023-E-3236-0002,FDA,FDA-2023-E-3236,"Patent Extension Application from Finnegan, Henderson, Farabow, Garrett & Dunner, LLP (on behalf of BioArtic AB)",Other,Application,2023-08-18T04:00:00Z,2023,8,2023-08-18T04:00:00Z,,2023-08-18T13:17:40Z,,0,0,0900006485da4b42